Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharming Group N.V (PHAR) Non Operating Income: 2020-2023

Historic Non Operating Income for Pharming Group N.V (PHAR) over the last 1 years, with Dec 2023 value amounting to -$3.8 million.

  • Pharming Group N.V's Non Operating Income rose 49.68% to -$3.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$14.1 million, marking a year-over-year decrease of 3020.54%. This contributed to the annual value of $1.9 million for FY2024, which is 129.81% up from last year.
  • As of Q4 2023, Pharming Group N.V's Non Operating Income stood at -$3.8 million, which was up 15.49% from -$4.5 million recorded in Q2 2023.
  • In the past 5 years, Pharming Group N.V's Non Operating Income ranged from a high of $8.8 million in Q4 2021 and a low of -$12.9 million during Q3 2020.
  • Over the past 3 years, Pharming Group N.V's median Non Operating Income value was -$1.2 million (recorded in 2021), while the average stood at -$656,750.
  • Its Non Operating Income has fluctuated over the past 5 years, first surged by 169.36% in 2021, then tumbled by 184.85% in 2022.
  • Quarterly analysis of 4 years shows Pharming Group N.V's Non Operating Income stood at -$12.7 million in 2020, then surged by 169.36% to $8.8 million in 2021, then plummeted by 184.85% to -$7.5 million in 2022, then spiked by 49.68% to -$3.8 million in 2023.
  • Its Non Operating Income stands at -$3.8 million for Q4 2023, versus -$4.5 million for Q2 2023 and -$7.5 million for Q4 2022.